arrow
T

Tracey L. O'Connor

Moffitt Cancer Center
H指数:32
被引数:4,083

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Systemic chemokine-modulatory regimen combined with neoadjuvant chemotherapy in patients with triple-negative breast cancer
2024-11-140
OAAI
Functional decline in older breast cancer survivors treated with and without chemotherapy and non-cancer controls: results from the Hurria Older PatiEnts (HOPE) prospective study

接受或不接受化疗和非癌症对照的老年乳腺癌幸存者的功能下降: 来自Hurria老年患者 (HOPE) 前瞻性研究的结果

2024-04-282
PRE
Lasofoxifene versus fulvestrant for ERD/HER2L metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial

Lasofoxifene与fulvestrant治疗ESR1突变的ERD/HER2L转移性乳腺癌: 来自随机,II期ELAINE 1试验的结果

2023-12-0112
OA
Falls prechemotherapy and toxicity-related hospitalization during adjuvant chemotherapy for breast cancer in older women: Results from the prospective multicenter HOPE trial
CANCER
IF5.1
2023-11-142
OAAI
Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influx
2023-11-149
OAAI
Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study

乳腺癌和新型冠状病毒肺炎患者的临床特征,种族不平等和结局: 新型冠状病毒肺炎和癌症联盟 (CCC19) 队列研究

2023-10-172
OA
Survivorship, Version 1.2023 Featured Updates to the NCCN Guidelines
2023-08-0122
OA
A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN)
2023-01-065
OAAI
Survivorship, Version 1.2022 Featured Updates to the NCCN Guidelines

Survivorship,1.2022版更新了NCCN指南

2022-10-0118
OA